Navigation Links
Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
Date:5/12/2009

SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Deutsche Bank Health Care Conference on Tuesday, May 19, 2009 at 11:30 a.m. ET / 8:30 a.m. PT in Boston. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.

The live presentation and breakout session will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate Web site, located at www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
2. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
3. Amylin Issues Statement in Response to Carl Icahn
4. Icahn Asks Amylin to Allow Discussions With Eastbourne
5. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
6. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
7. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
8. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
9. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
10. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
11. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... of 13 prestigious awards honoring scientists who have made outstanding ... a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for ...
(Date:10/9/2017)... (PRWEB) , ... October 09, ... ... published on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s ... the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using ...
(Date:10/6/2017)... ... October 06, 2017 , ... ... discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). ... Institute. The event is free and open to the public, but registration is ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):